Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells

Gynecologic Oncology

Volumn 121, Issue 1, 2011, Pages 187-192

  Teoh, Deanna ^a   Ayeni, Tina A ^a,b   Rubatt, Jennifer M ^a,c   Adams, David J ^a   Grace, Lisa ^a   Starr, Mark D ^a   Barry, William T ^a   Berchuck, Andrew ^a   Murphy, Susan K ^a   Secord, Angeles Alvarez ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Dasatinib; Ovarian cancer; SRC pathway

Indexed keywords

BMS 35482; CARBOPLATIN; CYTOTOXIC AGENT; DASATINIB; PACLITAXEL; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; GENOMICS; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; GENE EXPRESSION; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PROTO-ONCOGENE PROTEINS PP60(C-SRC); PYRIMIDINES; THIAZOLES;

EID: 79952816751     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.11.017     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Luo F, Barrett YC, Yang Z, et al. Identification and validation of phospho-Src, a novel and potential pharmacodynamic biomarker for dasatinib, a multi-targeted kinase inhibitor. Cancer Chemother Pharmacol 2008;62:1065-74.
3. Budde RJ, Ke S, Levin VA. Activity of pp 60c-Src in 60 different cell lines derived from human tumors. Cancer Biochem Biophys 1994;14:171-5.
4. Wiener JR, Windham TC, Estrella VC, et al. Activated Src protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 2003;88:73-9. (Pubitemid 36062670)
5. Dressman HK, Berchuck A, Chan G, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007;25:517-25. (Pubitemid 350002958)
6. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7. (Pubitemid 43128862)
7. Pengetnze Y, Steed M, Roby KF, et al. Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line. Biochem Biophys Res Commun 2003;309:377-83. (Pubitemid 37025902)
8. Chen T, Pengetnze Y, Taylor CC. Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. Mol Cancer Ther 2005;4:217-24. (Pubitemid 40340201)
9. Han L, Landen CN, Trevino JG, et al. Antiangiogenic and antitumor effects of Src inhibition in ovarian carcinoma. Cancer Res 2006;66:8633-9. (Pubitemid 44449178)
10. Wang X, Reeves K, Luo FR, et al. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol 2007;8:R255.
11. Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 2007;29:2289-308.
12. Gatza ML, Lucas JE, Barry WT, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci USA 2010;107:6994-9.
13. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
14. Chou T, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
15. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
16. Konecny GE, Glas R, Dering J, et al. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Br J Cancer 2009;101:1699-708.
17. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-300. (Pubitemid 44706932)
18. Demetri GD, Russo PL, MacPhersson IRJ, et al. Phase I dose-escalation and pharmacokinetic studies of dasatinib in patients with advanced solid tumors. Clin Cancer Res 2009;15:6232-40.
19. Mayer EL, Krop IE. Advances in targeting Src in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 2010;16:3526-32.
20. Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009;15:7421-8.
21. http://www.cancer.gov/search/ResultsClinicalTrials.aspx?protocolsearchid= 8245829.